Current and emerging pharmacotherapies for treating tobacco dependence

Bibliography

• CDC: Cigarette smoking among adults – United States, 2004. MMWR Morb. Mortal. Wkly Rep. (2005) 54:1121-1124.
   PubMedGoogle Scholar
• MACKAY M, ERIKSEN M: The Tobacco Atlas. World Health Organization (2002).
   Google Scholar
• CDC: Annual smoking-attributable mortality, years of potential Li lost, and productivity losses – United States, 1997 – 2001. MMWR Morb. Mortal. Wkly Rep. (2005) 54:625-628.
   PubMedGoogle Scholar
• CDC: Annual smoking-attributable mortality, years of potential life lost, and economic costs – United States, 1995 – 1999. MMWR Morb. Mortal. Wkly Rep. (2002) 5:300-303.
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders DSM-IV (4th edn). Washington, DC, USA (1994).
   Google Scholar
• BRESLAU N, JOHNSON E O, HIRIPI E, KESSLER R: Nicotine dependence in the United States: prevalence, trends, and smoking persistence. Arch. Gen. Psychiatry (2001) 58:810-816.
   PubMed Web of Science ®Google Scholar
• JOHN U, MEYER C, RUMPF HJ, SCHUMANN A, HAPKE U: Consistency or change in nicotine dependence according to the Fagerstrom Test for Nicotine Dependence over three years in a population sample. J. Addict Dis. (2005) 24:85-100.
   PubMed Web of Science ®Google Scholar
• FIORE MC, BAILEY WC, COHEN SJ et al.: Treating tobacco use and dependence. Clinical Practice Guideline. USDHHS, Rockville, MD, USA (2000).
   Google Scholar
• FRISHMAN WH, MITTA W, KUPERSMITH A, KY T: Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol. Rev. (2006) 14:57-73.
   PubMedGoogle Scholar
• FOULDS J: The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int. J. Clin. Pract. (2006) 50:571-576.
   Google Scholar
• HENNINGFIELD JE, FANT RV, BUCHHALTER AR, STITZER ML: Pharmacotherapy for nicotine dependence. CA Cancer J. Clin. (2005) 55:281-299; quiz 322-323, 325.
   PubMed Web of Science ®Google Scholar
• GONZALES D, RENNARD SI, NIDES M et al.: Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, versus sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA (2006) 296:47-55.
   PubMed Web of Science ®Google Scholar
• HUGHES J, STEAD L, LANCASTER T: Antidepressants for smoking cessation. Cochrane Database Syst. Rev. (2004):CD000031.
   Google Scholar
• SILAGY C, LANCASTER T, STEAD L, MANT D, FOWLER G: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. (2004) 3:CD000146.
   Google Scholar
• HUGHES JR, STEAD LF, LANCASTER T: Nortriptyline for smoking cessation: a review. Nicotine Tob. Res. (2005) 7:491-499.
   PubMed Web of Science ®Google Scholar
• WAGENA EJ, KNIPSCHILD P, ZEEGERS M PA: Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction (2005) 3:317-326.
   Google Scholar
• GLOVER ED, GLOVER PN, FRANZON M et al.: A comparison of a nicotine sublingual tablet and placebo for smoking cessation. Nicotine Tob. Res. (2002) 4:441-450.
   PubMedGoogle Scholar
• LERMAN C, KAUFMANN V, RUKSTALIS M et al.: Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann. Intern. Med. (2004) 1400:426-433.
   Google Scholar
• HENNINGFIELD JE, SCHUH LM, JARVIK M I: Pathophysiology of tobacco dependence. In: Psychopharmacology: The Fourth Generation of Progress. FE Bloom, DJ Kupfer (Eds), Raven Press, New York, USA (1995).
   Google Scholar
• LERMAN C, PATTERSON F, BERRETTINI W: Treating tobacco dependence: state of the science and new directions. J. Clin. Oncol. (2005) 23:311-323.
   PubMed Web of Science ®Google Scholar
• RICHMOND RL, HARRIS K, DE ALMEIDA NETO A: The transdermal nicotine patch: results of a randomised placebo-controlled trial. Med. J. Aust. (1994) 161:130-135.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER NG, OLMSTEAD R, MODY FV et al.: Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction (1995) 90:1671-1682.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER NG, JARVIK ME, FORSYTHE AB, READ LL, ELLIOTT ML, SCHWEIGER A: Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. Addict. Behav. (1983) 8:253-261.
   PubMed Web of Science ®Google Scholar
• SHIFFMAN S, DRESLER CM, HAJEK P, GILBURT SJ, TARGETT DA, STRAHS KR: Efficacy of a nicotine lozenge for smoking cessation. Arch. Intern. Med. (2002) 162:1267-1276.
   PubMed Web of Science ®Google Scholar
• TONNESEN P, NORREGAARD J, MIKKELSEN K, JORGENSEN S, NILSSON F: A double-blind trial of a nicotine inhaler for smoking cessation. JAMA (1993) 269:1268-1271.
   PubMed Web of Science ®Google Scholar
• SHIFFMAN S, HICKCOX M, PATY JA, GNYS M, KASSEL JD, RICHARDS TJ: Progression from a smoking lapse to relapse: prediction from abstinence violation effects, nicotine dependence, and lapse characteristics. J. Consult. Clin. Psychol. (1996) 64:993-1002.
   PubMed Web of Science ®Google Scholar
• NIAURA R, SAYETTE M, SHIFFMAN S et al.: Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction (2005) 100:1720-1730.
   PubMed Web of Science ®Google Scholar
• TONNESEN P, PAOLETTI P, GUSTAVSSON G et al.: Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur. Respir. J. (1999) 13:238-246.
   PubMed Web of Science ®Google Scholar
• DALE LC, HURT RD, OFFORD KP, LAWSON GM, CROGHAN IT, SCHROEDER DR: High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA (1995) 274:1353-1358.
   PubMed Web of Science ®Google Scholar
• JORENBY DE, SMITH SS, FIORE MC et al.: Varying nicotine patch dose and type of smoking cessation counseling. JAMA (1995) 274:1347-1352.
   PubMed Web of Science ®Google Scholar
• PAOLETTI P, FORNAI E, MAGGIORELLI F et al.: Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch. Eur. Respir. J. (1996) 9:643-651.
   PubMed Web of Science ®Google Scholar
• KORNITZER M, BOUTSEN M, DRAMAIX M, THIJS J, GUSTAVSSON G: Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev. Med. (1995) 24:41-47.
   PubMed Web of Science ®Google Scholar
• PUSKA P, KORHÔNEN HJ, VARTIAINEN E, URJANHEIMO E, GUSTAVSSON G, WESTIN A: Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tob. Control (1995) 4:231-235.
   Google Scholar
• BLONDAL T, GUDMUNDSSON LJ, OLAFSDOTTIR I, GUSTAVSSON G, WESTIN A: Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ (1999) 318:285-288.
   PubMed Web of Science ®Google Scholar
• TONNESEN P, MIKKELSEN KL: Smoking cessation with four nicotine replacement regimes in a lung clinic. Eur. Respir. J. (2000) 16:717-722.
   PubMed Web of Science ®Google Scholar
• CROGHAN GA, SLOAN JA, CROGHAN IT et al.: Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob. Res. (2003) 5:181-187.
   PubMed Web of Science ®Google Scholar
• ROSE JE, BEHM FM, WESTMAN EC, KUKOVICH P: Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob. Res. (2006) 8:89-101.
   PubMed Web of Science ®Google Scholar
• MCCLURE JB, SWAN GE: Tailoring nicotine replacement therapy: rationale and potential approaches. CNS Drugs (2006) 20:281-291.
   PubMed Web of Science ®Google Scholar
• GARVEY AJ, KINNUNEN T, NORDSTROM BL et al.: Effects of nicotine gum dose by level of nicotine dependence. Nicotine Tob. Res. (2000) 2:53-63.
   PubMedGoogle Scholar
• WEST R, HAJEK P, NILSSON F, FOULDS J, MAY S, MEADOWS A: Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology (Berl) (2001) 153:225-230.
   PubMed Web of Science ®Google Scholar
• CEPEDA-BENITO A, REYNOSO JT, ERATH S: Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. Journal of Counseling and Clinical Psychology (2004) 72:712-722.
   PubMed Web of Science ®Google Scholar
• WETTER DW, FIORE MC, YOUNG TB, MCCLURE JB, DE MOOR CA, BAKER TB: Gender differences in response to nicotine replacement therapy: objective and subjective indexes of tobacco withdrawal. Exp. Clin. Psychopharmacol. (1999) 7:135-144.
   PubMed Web of Science ®Google Scholar
• MUNAFO M, BRADBURN M, BOWES L, DAVID S: Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine Tob. Res. (2004) 6:769-776.
   PubMed Web of Science ®Google Scholar
• SHIFFMAN S, SWEENEY CT, DRESLER CM: Nicotine patch and lozenge are effective for women. Nicotine Tob. Res. (2005) 7:119-127.
   PubMed Web of Science ®Google Scholar
• WESTMAAS JL, LANGSAM K: Unaided smoking cessation and predictors of failure to quit in a community sample: effects of gender. Addict. Behav. (2005) 30:1405-1424.
   PubMed Web of Science ®Google Scholar
• MUNAFO MR, SHIELDS AE, BERRETTINI WH, PATTERSON F, LERMAN C: Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics (2005) 6:211-223.
   PubMed Web of Science ®Google Scholar
• VOLPP KG, GURMANKIN LEVY A, ASCH DA et al.: A randomized controlled trial of financial incentives for smoking cessation. Cancer Epidemiol. Biomarkers Prev. (2006) 15:12-18.
   PubMed Web of Science ®Google Scholar
• AHLUWALIA JS, HARRIS KJ, CATLEY D, OKUYEMI KS, MAYO MS: Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA (2002) 288:468-474.
   PubMed Web of Science ®Google Scholar
• COLLINS BN, WILEYTO EP, PATTERSON F et al.: Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob. Res. (2004) 6:27-37.
   PubMed Web of Science ®Google Scholar
• SCHARF D, SHIFFMAN S: Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR. Addiction (2004) 99:1462-1469.
   PubMed Web of Science ®Google Scholar
• DALE LC, GLOVER ED, SACHS DP et al.: Bupropion for smoking cessation: predictors of successful outcome. Chest (2001) 119:1357-1364.
   PubMed Web of Science ®Google Scholar
• ASCHER JA, COLE JO, COLIN JN et al.: Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry (1995) 56:395-401.
   PubMed Web of Science ®Google Scholar
• SLEMMER JE, MARTIN BR, DAMAJ MI: Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. (2000) 295:321-327.
   PubMed Web of Science ®Google Scholar
• LERMAN C, ROTH D, KAUFMANN V et al.: Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. (2002) 67:219-223.
   PubMed Web of Science ®Google Scholar
• HURT RD, SACHS DP, GLOVER ED et al.: A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. (1997) 337:1195-1202.
   PubMed Web of Science ®Google Scholar
• COX LS, PATTEN CA, NIAURA RS et al.: Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. J. Gen. Intern. Med. (2004) 19:828-834.
   PubMed Web of Science ®Google Scholar
• KILLEN JD, FORTMANN SP, MURPHY GM Jr et al.: Extended treatment with bupropion SR for cigarette smoking cessation. J. Consult. Clin. Psychol. (2006) 74:286-294.
   PubMed Web of Science ®Google Scholar
• SCHNOLL RA, LAZEV A, SOBEL M, TATUM K, BUTLER D, LERMAN C: Preliminary results from a randomized trial of bupropion for smoking cessation among cancer patients. Paper presented at: The 11th annual Society for Research on Nicotine and Tobacco meeting. Prague, The Czech Republic (2005).
   Google Scholar
• PAPKE RL, HEINEMANN SF: Partial agonist properties of cytisine on neuronal nicotinic receptors containing the β2 subunit. Mol. Pharmacol. (1994) 45:142-149.
   PubMed Web of Science ®Google Scholar
• COE JW, BROOKS PR, VETELINO MG et al.: Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. (2005) 48:3474-3477.
   PubMed Web of Science ®Google Scholar
• JORENBY DE, HAYS JT, RIGOTTI NA et al.: Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, versus placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA (2006) 296:56-63.
   PubMed Web of Science ®Google Scholar
• TONSTAD S, TONNESEN P, HAJEK P, WILLIAMS KE, BILLING CB, REEVES KR: Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA (2006) 296:64-71.
   PubMed Web of Science ®Google Scholar
• SICA DA, GRUBBS R: Transdermal clonidine: therapeutic considerations. J. Clin. Hypertens. (Greenwich) (2005) 7:558-562.
   Google Scholar
• MANHEM P, NILSSON L H, MOBERG A L, WADSTEIN J, HOKFELT B: Alcohol withdrawal: effects of clonidine treatment on sympathetic activity, the renin–aldosterone system, and clinical symptoms. Alcohol Clin. Exp. Res. (1985) 9:238-243.
   PubMed Web of Science ®Google Scholar
• GOURLAY SG, STEAD LF, BENOWITZ NL: Clonidine for smoking cessation. Cochrane Database Syst. Rev. (2004) 3:CD000058.
   Google Scholar
• GEORGE TP, O’MALLEY SS: Current pharmacological treatments for nicotine dependence. Trends Pharmacol. Sci. (2004) 25:42-48.
   PubMed Web of Science ®Google Scholar
• HALL SM, HUMFLEET GL, REUS VI, MUNOZ RF, HARTZ DT, MAUDE-GRIFFIN R: Psychological intervention and antidepressant treatment in smoking cessation. Arch. Gen. Psychiatry (2002) 59:930-936.
   PubMed Web of Science ®Google Scholar
• HAGGSTRAM FM, CHATKIN JM, SUSSENBACH-VAZ E, CESARI DH, FAM CF, FRITSCHER CC: A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. Pulm. Pharmacol. Ther. (2006) 19:205-209.
   PubMed Web of Science ®Google Scholar
• SHERMAN SE, YANO EM, LANTO AB, SIMON BF, RUBENSTEIN LV: Smokers’ interest in quitting and services received: using practice information to plan quality improvement and policy for smoking cessation. Am. J. Med. Qual. (2005) 20:33-39.
   PubMed Web of Science ®Google Scholar
• METZGER KB, MOSTASHARI F, KERKER BD: Use of pharmacy data to evaluate smoking regulations’ impact on sales of nicotine replacement therapies in New York City. Am. J. Public Health (2005) 95:1050-1055.
   PubMed Web of Science ®Google Scholar
• KOZLOWSKI LT, STRASSER AA, GIOVINO GA, ERICKSON PA, TERZA JV: Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tob. Control (2001) 10:201-203.
   PubMed Web of Science ®Google Scholar
• GRAY N, HENNINGFIELD JE, BENOWITZ NL et al.: Toward a comprehensive long term nicotine policy. Tob. Control (2005) 14:161-165.
   PubMed Web of Science ®Google Scholar
• BURTON SL, GITCHELL JG, SHIFFMAN S: Use of FDA-approved pharmacologic treatments for tobacco dependence – United States, 1984 – 1998. MMWR Morb. Mortal. Wkly Rep. (2000) 49:665-668.
   PubMedGoogle Scholar
• HYLAND A, REZAISHIRAZ H, GIOVINO G, BAUER JE, MICHAEL CUMMINGS K: Over-the-counter availability of nicotine replacement therapy and smoking cessation. Nicotine Tob. Res. (2005) 7:547-555.
   PubMed Web of Science ®Google Scholar
• REED MB, ANDERSON CM, VAUGHN JW, BURNS DM: The effect of over-the-counter sales of the nicotine patch and nicotine gum on smoking cessation in California. Cancer Epidemiol. Biomarkers Prev. (2005) 14:2131-2136.
   PubMed Web of Science ®Google Scholar
• KEELER TE, HU TW, KEITH A et al.: The benefits of switching smoking cessation drugs to over-the-counter status. Health Econ. (2002) 11:389-402.
   PubMed Web of Science ®Google Scholar
• WEST R, DIMARINO ME, GITCHELL J, MCNEILL A: Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tob. Control (2005) 14:166-171.
   PubMed Web of Science ®Google Scholar
• CUMMINGS K M, FIX B, CELESTINO P, CARLIN-MENTER S, O’CONNOR R, HYLAND A: Reach, efficacy, and cost-effectiveness of free nicotine medication giveaway programs. J. Public Health Manag. Pract. (2006) 12:37-43.
   PubMed Web of Science ®Google Scholar
• MILLER N, FRIEDEN TR, LIU SY et al.: Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation. Lancet (2005) 365:1849-1854.
   PubMed Web of Science ®Google Scholar
• PAUL CL, WIGGERS J, DALY J B et al.: Direct telemarketing of smoking cessation interventions: will smokers take the call? Addiction (2004) 99:907-913.
   PubMed Web of Science ®Google Scholar
• TAURAS JA, CHALOUPKA FJ, EMERY S: The impact of advertising on nicotine replacement therapy demand. Soc. Sci. Med. (2005) 60:2351-2358.
   PubMed Web of Science ®Google Scholar
• DANI JA, HARRIS RA: Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat. Neurosci. (2005) 8:1465-1470.
   PubMed Web of Science ®Google Scholar
• NESTLER EJ: Is there a common molecular pathway for addiction? Nat. Neurosci. (2005) 8:1445-1449.
   PubMed Web of Science ®Google Scholar
• LAVIOLETTE SR, VAN DER KOOY D: The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat. Rev. Neurosci. (2004) 5:55-65.
   PubMed Web of Science ®Google Scholar
• MA Z, STRECKER RE, MCKENNA JT, THAKKAR MM, MCCARLEY RW, TAO R: Effects on serotonin of (-)nicotine and dimethylphenylpiperazinium in the dorsal raphe and nucleus accumbens of freely behaving rats. Neuroscience (2005) 135:949-958.
   PubMed Web of Science ®Google Scholar
• BARIK J, WONNACOTT S: Indirect modulation by α7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal. Mol. Pharmacol. (2006) 69:618-628.
   PubMed Web of Science ®Google Scholar
• BOYADJIEVA NI, SARKAR DK: The secretory response of hypothalamic β-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci. (1997) 61:PL59-PL66.
   Google Scholar
• DAVENPORT KE, HOUDI AA, VAN LOON GR: Nicotine protects against µ-opioid receptor antagonism by β-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci. Lett. (1990) 113:40-46.
   PubMed Web of Science ®Google Scholar
• HOUDI A A, PIERZCHALA K, MARSON L, PALKOVITS M, VAN LOON GR: Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides (1991) 12:161-166.
   PubMed Web of Science ®Google Scholar
• PIEZCHALA K, HOUDI AA, VAN LOON GR: Nicotine-induced alterations in brain regional concentrations of native and cryptic Met- and Leu-enkephalin. Peptides (1987) 8:1035-1043.
   PubMed Web of Science ®Google Scholar
• KENNY PJ, MARKOU A: Neurobiology of the nicotine withdrawal syndrome. Pharmacol. Biochem. Behav. (2001) 70:531-549.
   PubMed Web of Science ®Google Scholar
• FOULDS J, BURKE M, STEINBERG M, WILLIAMS JM, ZIEDONIS DM: Advances in pharmacotherapy for tobacco dependence. Expert Opin. Emerging Drugs (2004) 9:39-53.
   PubMedGoogle Scholar
• WEST R, HAJEK P: Randomised controlled trial of ondansetron in smoking cessation. Psychopharmacology (Berl) (1996) 126:95-96.
   PubMed Web of Science ®Google Scholar
• FOWLER JS, VOLKOW ND, WANG GJ et al.: Inhibition of monoamine oxidase B in the brains of smokers. Nature (1996) 379:733-736.
   PubMed Web of Science ®Google Scholar
• FOWLER JS, VOLKOW ND, WANG GJ et al.: Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. USA (1996) 93:14065-14069.
   PubMed Web of Science ®Google Scholar
• GUILLEM K, VOUILLAC C, AZAR MR et al.: Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J. Neurosci. (2005) 25:8593-8600.
   PubMed Web of Science ®Google Scholar
• ROSE JE: Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl) (2006) 184:274-285.
   PubMed Web of Science ®Google Scholar
• BERLIN I, AUBIN HJ, PEDARRIOSSE AM, RAMES A, LANCRENON S, LAGRUE G: Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Addiction (2002) 97:1347-1354.
   PubMed Web of Science ®Google Scholar
• BIBERMAN R, NEUMANN R, KATZIR I, GERBER Y: A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction (2003) 98:1403-1407.
   PubMed Web of Science ®Google Scholar
• BERLIN I, SAID S, SPREUX-VAROQUAUX O et al.: A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin. Pharmacol. Ther. (1995) 58:444-452.
   PubMed Web of Science ®Google Scholar
• COVEY LS, GLASSMAN AH, STETNER F, RIVELLI S, STAGE K: A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am. J. Psychiatry (2002) 159:1731-1737.
   PubMed Web of Science ®Google Scholar
• KILLEN JD, FORTMANN SP, SCHATZBERG AF et al.: Nicotine patch and paroxetine for smoking cessation. J. Consult. Clin. Psychol. (2000) 68:883-889.
   PubMed Web of Science ®Google Scholar
• HITSMAN B, PINGITORE R, SPRING B et al.: Antidepressant pharmacotherapy helps some cigarette smokers more than others. J. Consult. Clin. Psychol. (1999) 67:547-554.
   PubMed Web of Science ®Google Scholar
• BLONDAL T, GUDMUNDSSON LJ, TOMASSON K et al.: The effects of fluoxetine combined with nicotine inhalers in smoking cessation – a randomized trial. Addiction (1999) 94:1007-1015.
   PubMed Web of Science ®Google Scholar
• SAULES KK, SCHUH LM, ARFKEN CL, REED K, KILBEY MM, SCHUSTER CR: Double-blind placebo-controlled trial of fluoxetine in smoking cessation treatment including nicotine patch and cognitive-behavioral group therapy. Am. J. Addict. (2004) 13:438-446.
   PubMed Web of Science ®Google Scholar
• NIAURA R, SPRING B, BORRELLI B et al.: Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J. Consult. Clin. Psychol. (2002) 70:887-896.
   PubMed Web of Science ®Google Scholar
• CINCIRIPINI PM, TSOH JY, WETTER DW et al.: Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Exp. Clin. Psychopharmacol. (2005) 13:282-292.
   PubMed Web of Science ®Google Scholar
• DAVID S, LANCASTER T, STEAD LF: Opioid antagonists for smoking cessation. Cochrane Database Syst. Rev. (2001):CD003086.
   Google Scholar
• COVEY LS, GLASSMAN AH, STETNER F: Naltrexone effects on short-term and long-term smoking cessation. J. Addict Dis. (1999) 18:31-40.
   PubMed Web of Science ®Google Scholar
• KRISHNAN-SARIN S, MEANDZIJA B, O’MALLEY S: Naltrexone and nicotine patch smoking cessation: a preliminary study. Nicotine Tob. Res. (2003) 5:851-857.
   PubMed Web of Science ®Google Scholar
• BYARS JA, FROST-PINEDA K, JACOBS WS, GOLD MS: Naltrexone augments the effects of nicotine replacement therapy in female smokers. J. Addict Dis. (2005) 24:49-60.
   PubMed Web of Science ®Google Scholar
• WONG GY, WOLTER TD, CROGHAN GA, CROGHAN IT, OFFORD KP, HURT RD: A randomized trial of naltrexone for smoking cessation. Addiction (1999) 94:1227-1237.
   PubMed Web of Science ®Google Scholar
• O’MALLEY SS, COONEY JL, KRISHNAN-SARIN S et al.: A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch. Intern. Med. (2006) 166:667-674.
   PubMed Web of Science ®Google Scholar
• BEVINS RA, BESHEER J, PICKETT KS: Nicotine-conditioned locomotor activity in rats: dopaminergic and GABAergic influences on conditioned expression. Pharmacol. Biochem. Behav. (2001) 68:135-145.
   PubMed Web of Science ®Google Scholar
• DEWEY SL, BRODIE JD, GERASIMOV M, HORAN B, GARDNER EL, ASHBY CR Jr: A pharmacologic strategy for the treatment of nicotine addiction. Synapse (1999) 31:76-86.
   PubMed Web of Science ®Google Scholar
• SOFUOGLU M, MOURATIDIS M, YOO S, CULLIGAN K, KOSTEN T: Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) (2005) 181:504-510.
   PubMed Web of Science ®Google Scholar
• PATERSON NE, FROESTL W, MARKOU A: The GABAB receptor agonists baclofen and CGP-44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl) (2004) 172:179-186.
   PubMed Web of Science ®Google Scholar
• COUSINS MS, STAMAT HM, DE WIT H: Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine Tob. Res. (2001) 3:123-129.
   PubMedGoogle Scholar
• CHENG JK, CHIOU LC: Mechanisms of the antinociceptive action of gabapentin. J. Pharmacol. Sci. (2006) 100:471-486.
   PubMed Web of Science ®Google Scholar
• WHITE WD, CROCKFORD D, PATTEN S, EL-GUEBALY N: A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine Tob. Res. (2005) 7:809-813.
   PubMed Web of Science ®Google Scholar
• MCCLERNON FJ, ROSE JE: Mecamylamine moderates cue-induced emotional responses in smokers. Addict. Behav. (2005) 30:741-753.
   PubMed Web of Science ®Google Scholar
• POMERLEAU CS, POMERLEAU OF, MAJCHRZAK MJ: Mecamylamine pretreatment increases subsequent nicotine self-administration as indicated by changes in plasma nicotine level. Psychopharmacology (Berl) (1987) 91:391-393.
   PubMed Web of Science ®Google Scholar
• ROSE JE, BEHM FM, WESTMAN EC: Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp. Clin. Psychopharmacol. (1998) 6:331-343.
   PubMed Web of Science ®Google Scholar
• ROSE JE, BEHM FM, WESTMAN EC, LEVIN ED, STEIN RM, RIPKA GV: Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. (1994) 56:86-99.
   PubMed Web of Science ®Google Scholar
• LANCASTER T, STEAD LF: Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst. Rev. (2000):CD001009.
   Google Scholar
• LESAGE MG, KEYLER DE, PENTEL PR: Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS J. (2006) 8:E65-E75.
   PubMed Web of Science ®Google Scholar
• MAURER P, JENNINGS GT, WILLERS J et al.: A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. (2005) 35:2031-2040.
   PubMed Web of Science ®Google Scholar
• DE VILLIERS SH, LINDBLOM N, KALAYANOV G et al.: Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration (2002) 69:247-253.
   PubMed Web of Science ®Google Scholar
• CORNUZ J, KILINGLER K, MUELLER P: A therapeutic vaccine for nicotine dependence: results of Phase I and a randomized Phase II study. Presented at: The American Society of Clinical Oncology. Orlando, Florida, USA (2005).
   Google Scholar
• HATSUKAMI DK, RENNARD S, JORENBY D et al.: Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther. (2005) 78:456-467.
   PubMed Web of Science ®Google Scholar
• CASTANE A, VALJENT E, LEDENT C, PARMENTIER M, MALDONADO R, VALVERDE O: Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology (2002) 43:857-867.
   PubMed Web of Science ®Google Scholar
• COHEN C, KODAS E, GRIEBEL G: CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol. Biochem. Behav. (2005) 81:387-395.
   PubMed Web of Science ®Google Scholar
• DALE L, ANTHENELLI R: Rimonabant as an aid to smoking cessation in smokers motivated to quit: results from a US multicenter study – STRATUS-US trial. Presented at: American College of Cardiology. New Orleans, USA (2004).
   Google Scholar
• GELFAND EV, CANNON C P: Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin. Investig. Drugs (2006) 15:307-315.
   PubMed Web of Science ®Google Scholar
• MOGHADDAM B, BOLINAO ML: Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release. Synapse (1994) 18:337-342.
   PubMed Web of Science ®Google Scholar
• CHESEAUX M, MONNAT M, ZULLINO DF: Topiramate in benzodiazepine withdrawal. Hum. Psychopharmacol. (2003) 18:375-377.
   PubMed Web of Science ®Google Scholar
• ZULLINO DF, COTTIER AC, BESSON J: Topiramate in opiate withdrawal. Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) 26:1221-1223.
   PubMed Web of Science ®Google Scholar
• JOHNSON B A, AIT-DAOUD N, BOWDEN CL et al.: Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet (2003) 361:1677-1685.
   PubMed Web of Science ®Google Scholar
• KAMPMAN KM, PETTINATI H, LYNCH KG et al.: A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. (2004) 75:233-240.
   PubMed Web of Science ®Google Scholar
• JOHNSON BA, AIT-DAOUD N, AKHTAR FZ, JAVORS MA: Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers. Arch. Intern. Med. (2005) 165:1600-1605.
   PubMed Web of Science ®Google Scholar
• SOFUOGLU M, POLING J, MOURATIDIS M, KOSTEN T: Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) (2006) 184:645-651.
   PubMed Web of Science ®Google Scholar
• EVANS WE, RELLING MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 286:487-491.
   PubMed Web of Science ®Google Scholar
• POOLSUP N, LI WAN PO A, KNIGHT TL: Pharmacogenetics and psychopharmacotherapy. J. Clin. Pharm. Ther. (2000) 25:197-220.
   PubMed Web of Science ®Google Scholar
• LERMAN C, SHIELDS PG, WILEYTO EP et al.: Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics (2002) 12:627-634.
   PubMedGoogle Scholar
• MIKSYS S, LERMAN C, SHIELDS PG, MASH DC, TYNDALE RF: Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology (2003) 45:122-132.
   PubMed Web of Science ®Google Scholar
• SWAN GE, VALDES AM, RING HZ et al.: Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J. (2005) 5:21-29.
   PubMed Web of Science ®Google Scholar
• DAVID SP, BROWN RA, PAPANDONATOS GD et al.: Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob. Res. (In Press).
   Google Scholar
• LERMAN C, JEPSON C, WILEYTO EP et al.: Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology (2006) 31:231-242.
   PubMed Web of Science ®Google Scholar
• BERRETTINI WH: Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol. Psychiatry (In Press).
   Google Scholar
• MALAIYANDI V, LERMAN C, BENOWITZ NL, JEPSON C, PATTERSON F, TYNDALE RF: Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol. Psychiatry (2006) 11:400-409.
   PubMed Web of Science ®Google Scholar
• LERMAN C, TYNDALE R, PATTERSON F et al.: Nicotine metabolite ratio predicts the efficacy of transdermal nicotine for smoking cessation. Clin. Pharmacol. Ther. (2006) 79(6):600-608.
   PubMed Web of Science ®Google Scholar
• YUDKIN P, MUNAFO M, HEY K et al.: Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ (2004) 328:989-990.
   PubMed Web of Science ®Google Scholar
• JOHNSTONE EC, YUDKIN PL, HEY K et al.: Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics (2004) 14:83-90.
   PubMedGoogle Scholar
• DAHL JP, JEPSON C, LEVENSON R et al.: Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics J. (2006) 6:194-199.
   PubMed Web of Science ®Google Scholar
• COLILLA S, LERMAN C, SHIELDS PG et al.: Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet. Genomics (2005) 15:393-398.
   PubMed Web of Science ®Google Scholar
• LERMAN C, WILEYTO EP, PATTERSON F et al.: The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. (2004) 4:184-192.
   PubMed Web of Science ®Google Scholar
• EVANS WE, RELLING MV: Moving towards individualized medicine with pharmacogenomics. Nature (2004) 429:464-468.
   PubMed Web of Science ®Google Scholar